Skip to main navigation menu Skip to main content Skip to site footer

Review article: Medical guidelines

Vol. 151 No. 3334 (2021)

Swiss germ-cell cancer consensus recommendations

  • Jörg Beyer
  • Dominik Berthold
  • Peter-Karl Bode
  • Richard Cathomas
  • Christian D. Fankhauser
  • Stefanie Fischer
  • Silke Gillessen
  • Tobias Gross
  • Thomas Hermanns
  • Friedemann Honecker
  • Anja Lorch
  • Aurelius Omlin
  • Alexandros Papachristofilou
  • Beat Roth
  • Christian Rothermundt
  • Roland Seiler
  • Martin Spahn
  • Frank Stenner
  • Emanuel Bührer
Cite this as:
Swiss Med Wkly. 2021;151:w30023


Approximately 420 men are diagnosed with germ-cell cancer (GCC) in Switzerland each year. Recent international guidelines outline management issues, but many aspects remain controversial in an area of highly individualised treatments. Even more than in other tumour types, in GCC the challenge is to choose exactly the correct treatment for an individual patient. Overtreatment in patients likely to be cured must be avoided to reduce long-term toxicities. On the other hand, treatment intensification is required in patients presenting with adverse prognostic factors. Therefore, referral to expert centres or consultations with an expert for a second opinion is strongly recommended. In 2020, Swiss experts discussed their strategies in a consensus meeting during the virtual Swiss Oncology and Haematology Congress (SOHC) in order to harmonise their concepts and to suggest optimal strategies for the management of GCC patients in Switzerland. Votes on controversial issues were obtained and are presented in this review wherever applicable.


  1. Gilligan T, Lin DW, Aggarwal R, Chism D, Cost N, Derweesh IH, et al. Testicular cancer, version 2.2020. J Natl Compr Canc Netw. 2019 Dec;17(12):1529–54.
  2. Honecker F, Aparicio J, Berney D, Beyer J, Bokemeyer C, Cathomas R, et al. ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up. Ann Oncol. 2018 Aug;29(8):1658–86.
  3. Albers P, Albrecht W, Algaba F, Bokemeyer C, Cohn-Cedermark G, Fizazi K, et al.; European Association of Urology. Guidelines on Testicular Cancer: 2015 Update. Eur Urol. 2015 Dec;68(6):1054–68.
  4. AJCC. AJCC Cancer Staging Manual. Berlin: Springer International Publishing; 2017.
  5. Mead GM ; International Germ Cell Cancer Collaborative Group. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol. 1997 Feb;15(2):594–603.
  6. Beyer J, Collette L, Sauvé N, Daugaard G, Feldman DR, Tandstad T, et al.; International Germ Cell Cancer Classification Update Consortium. Survival and New Prognosticators in Metastatic Seminoma: Results From the IGCCCG-Update Consortium. J Clin Oncol. 2021 May;39(14):1553–62.
  7. Gillessen S, Sauvé N, Collette L, Daugaard G, de Wit R, Albany C, et al.; International Germ Cell Cancer Classification Update Consortium. Predicting outcomes in men with metastatic nonseminomatous germ-cell tumors (NSGCT): Results from the IGCCCG-Update Consortium. J Clin Oncol. 2021 May;39(14):1563–74.
  8. Fankhauser CD, Sander S, Roth L, Beyer J, Hermanns T. Improved survival in metastatic germ-cell cancer. Ann Oncol. 2018 Feb;29(2):347–51.
  9. Rothermundt C, Thurneysen C, Cathomas R, Müller B, Mingrone W, Hirschi-Blickenstorfer A, et al. Baseline characteristics and patterns of care in testicular cancer patients: first data from the Swiss Austrian German Testicular Cancer Cohort Study (SAG TCCS). Swiss Med Wkly. 2018 Jul;148:w14640.
  10. Cathomas R, Klingbiel D, Bernard B, Lorch A, Garcia Del Muro X, Morelli F, et al. Questioning the Value of Fluorodeoxyglucose Positron Emission Tomography for Residual Lesions After Chemotherapy for Metastatic Seminoma: Results of an International Global Germ Cell Cancer Group Registry. J Clin Oncol. 2018 Oct;36(34):JCO1800210.
  11. Fankhauser CD, Gerke TA, Roth L, Sander S, Grossmann NC, Kranzbühler B, et al. Pre-orchiectomy tumor marker levels should not be used for International Germ Cell Consensus Classification (IGCCCG) risk group assignment. J Cancer Res Clin Oncol. 2019 Mar;145(3):781–5.
  12. Lauritsen J, Hansen MK, Bandak M, Kreiberg MB, Skøtt JW, Wagner T, et al. Cardiovascular risk factors and disease after male germ cell cancer. J Clin Oncol. 2020 Feb;38(6):584–92.

Most read articles by the same author(s)

1 2 > >>